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The British Journal of Dermatology (BJD) editorial board now includes five associate editors who review 
the methodological reporting of articles submitted to the BJD.  In order to assure successful publication 
of high quality research submitted to the BJD it is of utmost important that methods and results are 
described in sufficient detail by authors. The BJD author guidelines, editorials on reporting and reporting 
guidelines all contribute to achieving this goal 1-3. Here, we would like to highlight a few general and 
study-specific issues. 
 
Always Be Clear about the study design 
The design is the most essential part of conducting a study. Most flaws in clinical research are a result of 
poor planning. Inappropriate study design cannot be fixed during the analyses phase and does therefore 
not lead to an answer to the research question. The statistical analyses are dependent on correct study 
design. A clear and detailed research question should lead to determining the appropriate outcome 
measure. When designing the study, the outcome measure and how and when the outcome should be 
measured, determines the type of analyses that will be conducted at the end of the study. 
 
Always Be Clear about the purpose of each analysis 
The aim of describing the methods is that the knowledgeable reader with access to the original data has 
sufficient detail to verify the reported results 4. It is thus not sufficient to sum up all statistical analyses 
used, but the authors need to specify which test was used for which purpose. For example: ‘a two-
sample independent t-test was used to compare continues data between 2 groups’, tells the reader 
what can be read from any statistical textbook, but doesn’t tell the reader for which comparison the 
authors used a t-test and if an independent sample t-test was thus the appropriate test. The author 
needs to specify for which study specific aim the statistical test was used, e.g. ‘a two-sample 
independent t-test was used to compare the body weight between patients and controls’. 
 
Always Be Clear when reporting the results 
Results should be described in such a way, that the results can be incorporated into other analyses 4.  
To re-use reported data for meta-analyses, requires that numerators and denominators of percentages, 
risks, odds and hazards ratios are reported. Also, reporting p-values only is not sufficient: descriptive 
statistics of the groups, sample size, effect size and a measure of precision (standard error or 95% 
confidence interval) should be reported. In addition, actual p-values should be reported, rather than 
referencing p-values to a critical value (e.g. p=0.006 instead of p<0.05). 
 
Clinical Trials: Always Be Clear about the analysis plan and interpretation of 
results  
For sake of transparence, authors should develop a statistical analysis plan, a prospective document that 
specifies how trial data will be analysed 5. The analysis plan could either be a stand-alone document or be 
integrated into the protocol. The document should be signed off before blindness had to be broken, and 
before any analysis has started. Any deviations from the signed-off plan should be clearly explained. 
Adherence to the CONSORT reporting guidelines facilitates transparency of reporting, genuine and 
accurate interpretation of results 6. In most of the clinical trial papers submitted to BJD in 2017-2018, 
the CONSORT 2010 checklist, which is only appropriate for the individually randomised, two groups, 
parallel trials, was completed6.  Extended CONSORT checklists have been developed for 1) other designs 
such as cluster randomized trial, non-inferiority and equivalent trial, or pilot study and 2) other 
interventions including non-pharmacologic treatment interventions, herbal medicinal interventions or 
acupuncture interventions.  Given the continuous evolving nature of the CONSORT guidelines, authors 
are strongly recommended to visit the CONSORT website to be sure the most up-to-date checklist is 
used.  
 
Epidemiology: Always Be Clear about assumptions in regression analyses 
Regression analyses are frequently used in epidemiological studies. Authors need to state in the 
methods, how the model assumptions were tested, if they were met and (if applicable) what has been 
done when the assumptions were not met. For linear regression analyses these assumptions include: 
independence of observations, linear relation between covariate and outcome, normal distribution of 
the residuals (differences between the observed and predicted values), the same standard deviation of 
the residuals across every value of the predictor (homoscedasticity) 7. The linearity assumption also 
applies to other regression models (e.g.  Logistic, Cox, Poisson).  Non-linear relationships can be included 
in regression models by including non-linear functions (most accurate) or categorize continues variables 
(simple, easy to interpret). When a Cox proportional hazards model is applied to survival data, the 
proportional hazards assumption should be tested 8. 
 
Genomics: Always Be Clear about your analyzed DNA and RNA data given the very 
'noisy' background  
Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) methods are used to detect 
causative DNA mutations in an individual. These procedures provide a long list of variants in the DNA of 
the tested individual. The list of variants is dependent on: (i) the depth of the run. For example, an 
average of 100X coverage over the DNA would generate more variants than a 20x coverage read; (ii) the 
similarity to the reference DNA. For example, an African American DNA aligned against a European 
reference DNA would generate a vast amount of non-matching variants. These and other parameters 
affect the probability of locating a detrimental causative mutation and should therefore be reported in 
the methods.   
Changes in cellular RNA levels possesses information on the state and function of samples. Most 
commonly used is the expression analysis of mRNA using sequencing technologies (RNA-seq), which 
allows biologists to identify gene and transcript expression under two or more conditions, and also to 
identify new genes and new splice variants. RNA-seq experiments must be analyzed with robust, 
efficient and statistically principled algorithms. Fortunately, the bioinformatics community has 
developed mathematical and statistical tools for RNA-seq processing presented as downloadable 
software or online tools, which must be specified in the methods section. Many other sophisticated 
procedures prior to data generation increase biological insight. For example, CLIP (cross-
linking immunoprecipitation) is used in order to analyze protein interactions with RNA 9. These should 
be clearly described in the manuscript.  
 
Systematic Reviews and Meta-Analyses: Always Be Clear about the analysis 
methods for pooling studies  
The choice over using a fixed or random effects models need to be declared within the methods section. 
Random effects models should be the default as this model allows for the magnitude of effect for the 
treatment or association to vary by study and patient level characteristics. The fixed effect model should 
only be used where there is a strong rationale that there could be a single magnitude of effect for the 
treatment or association being investigated.    
It is important that the variation between studies, known as heterogeneity, is fully investigated 10– two 
methods commonly used are subgroup analysis and sensitivity analysis. Subgroup analysis is used to 
determine whether the pooled effect size varies between subgroups, for example high versus low 
methodological quality, using a statistical test. In contrast, a sensitivity analysis compares the magnitude 
of the pooled effect between a restricted set of studies, for example where poorer methodological 
quality studies are excluded, and the magnitude of the pooled effect from the overall meta-analysis. It is 
important that the characteristics to be investigated are biologically plausible and specified a-priori. The 
results from subgroup and sensitivity analyses should be only treated as exploratory since there is the 
potential for an association to be found purely by chance or due to other confounding factors. 
 
Translational Research: Always Be Clear about accounting for multiplicity in 
hypothesis testing 
Most studies do not test a single hypothesis, but rather cast a wide net for of interesting associations. It 
is absolutely not valid to perform all tests at the nominal level of significance required (which is typically 
0.05) and declare as significant associations that pass this threshold. This invalidity is easy to state and 
explain, since performing 50 tests at level 0.05 essentially guarantees some findings will be made, even 
if there is nothing to find (from the definition of what test level means). What should be done to correct 
it may be more scenario-dependent and in some cases can be hard to figure out. The simplest 
adjustment  is the Bonferroni correction (dividing the alpha-level by the number of tests). In some  cases 
the Benjamini-Hochberg (BH) type methods for controlling the false discovery rate (FDR) can also be 
appropriate 11. More advanced aspects include accounting for exploratory analysis, and dividing the 
tests into “primary” and “secondary” analyses, which can drive complex, but still valid, testing schemes 
12.   
 
Always Be Clear about the use of reporting guidelines  
Reporting guidelines include many of the aforementioned statistical and methodological items, which 
should be described in your manuscript 3. All recommended reporting guidelines can be found in the BJD 
author guidelines 2. The use of reporting guidelines will contribute to manuscripts with transparently 
reported methods and results, which are always clear!  
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